Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of trastuzumab deruxtecan in HER2-expressing recurrent or metastatic salivary gland carcinoma
jRCT2011210017Phase 2Active, not recruiting
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Jun 2021
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of trastuzumab deruxtecan in salivary gland cancer (SGC), sponsored by Daiichi Sankyo Co., Ltd. Primary endpoint: Objective response rate by the Independent Central Image Committee. Started Jun 2021; status: active, not recruiting.
02
Drugs
trastuzumab deruxtecan
03
Conditions
salivary gland cancer (SGC)
Beyond the preview
Go deeper on jRCT2011210017.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2011210017.